Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology - Germany
doi 10.1007/s00228-011-1115-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tendons – Time to Revisit Inflammation

British Journal of Sports Medicine
Sports MedicinePhysical TherapySports ScienceSports TherapyOrthopedicsMedicineRehabilitation
2013English

Time to Revisit VEP Monitoring?

Acta Neurochirurgica
SurgeryNeurology
2010English

Innovative Oncology Products: Time to Revisit the Strategy Development?

ESMO Open
Cancer ResearchOncology
2019English

Psy135 - Access to Orphan Drugs – Regulation Within the European Law

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Time to Revisit the Definition and Clinical Criteria for Anaphylaxis?

World Allergy Organization Journal
ImmunologyPulmonaryAllergyRespiratory Medicine
2019English

The Effect of the Orphan Drug Development Support Program.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1999English

Drug Screening to Target Nuclear Orphan Receptor NR4A2 for Cancer Therapeutics

Translational Lung Cancer Research
Oncology
2017English

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

Is It Time to Revisit the Pedersen Hypothesis in the Face of the Obesity Epidemic?

Obstetric Anesthesia Digest
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy